1355 GMT - Novartis CEO Vas Narasimhan is confident in the midterm outlook for the company, with drug launches set to lift top-line growth next year, Bank of America analysts say. Speaking at a Bank of America conference, Narasimhan struck a bullish tone on the Swiss drugmaker's prospects for the 2026-31 period and signaled previous guidance of sales growth of 5% to 6% in the five years through 2030 would be extended to 2031 at an update scheduled for November, the analysts say. Sales growth looks set to accelerate next year relative to the second half of 2026, when the company expects to post a mid single-digit percentage increase, and its performance at the end of the fourth quarter will be the best proxy, the analysts add. Shares rise 1.5%.
At the request of the copyright holder, you need to log in to view this content
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.